Group 1 - The core viewpoint of the article highlights that Clear Medical (01406) has established itself as the only ophthalmic center in Hong Kong offering a comprehensive advanced refractive treatment product portfolio, further solidifying its technological leadership in the market [1] - The company's business performance has shown resilience, with patient visits, new patient appointments, and surgical volumes in December 2025 reaching or exceeding levels from the same period in the past two years [1] - Clear Medical ranked first in Hong Kong for ICL surgeries in 2025, marking the third consecutive year of industry leadership [1] Group 2 - The company has incurred significant professional fees exceeding HKD 15 million due to ongoing allegations against former directors, which have created a substantial financial burden that could have been allocated to business development and shareholder returns [1] - The company is committed to efficiently completing the investigation related to the allegations and expediting the resumption of its shares, allowing management to refocus on executing its long-term strategic priorities [1] - The latest resumption guidelines include directives on investigation and rectification, integrity, internal controls, corporate governance, disclosure, financial reporting, and compliance with specific regulations [2]
清晰医疗(01406)业务表现持续稳健 2025年以ICL手术量位居香港榜首 实现连续第三年蝉联业界第一